
Our Work Projects
This is a programme of research in the area of psychosis that has been funded by the Health Research Board (HRB) and it consists of six work packages, each will address a key neglected area in psychotic disorders. The overall project will culminate into revised, holistic and comprehensive clinical guidelines for the management of psychotic disorders.
Supported decision making in selecting antipsychotic medications
To develop a co-designed supported decision-making application for the choice of the first antipsychotic medication. The different antipsychotic medications do not vary much in regards to their effectiveness. However, they differ in terms of their associated side-effect profiles. It is hypothesised that increasing the autonomy of clinical decision-making for a service user and supporting them in choosing a medication with a more acceptable side-effect profile will result in greater satisfaction and improved outcomes.
Maintaining or improving physical health in people affected by psychosis
Aiming to prevent the weight gain and metabolic complications associated with antipsychotic medications by proactively using medications such as metformin and Glucagon-like-peptide1-receptor agonists. In this work package, a clinical guideline for the use of metformin to prevent antipsychotic-induced weight gain will be developed and then evaluated in a cluster-designed study. Resources will be developed to inform clinicians and service users on how metformin can be used to prevent weight gain.
Identifying treatment resistance and reducing barriers to using clozapine
Address the delays and barriers to the commencement of clozapine, which is the most effective antipsychotic medication and the only one licenced for treatment-resistant psychosis. In this work package, a national survey of consultant psychiatrists will be conducted, and a pilot service for the community initiation of clozapine and point-of-care testing for blood tests will be established and evaluated. Three clinical guidelines will be developed in relation to clozapine. First, a guideline and protocol for the community initiation of clozapine will be developed and this will help in reducing hospital admissions. Second, a guideline on how to proactively manage the associated side effects of clozapine will be developed from existing evidence and third, a guideline for treatment when people do not respond to clozapine will be developed.
Special considerations for prescribing of antipsychotic medications in females
Address special considerations for prescribing antipsychotic medications for females affected by psychotic disorders. The prescribing needs differ for females before and after the menopause, as oestrogen can increase the effectiveness of certain antipsychotic medications. Therefore, lower doses are required prior to the peri-menopause and higher doses afterwards, yet this is not reflected in current guidelines, leading to high rates of relapse for females. There is also emerging evidence that the use of Hormone Replacement Therapy (HRT) in females with a diagnosis of schizophrenia can reduce the risk of relapse after the age of 45, and in this work package, we will determine the attitudes of psychiatrists and general practitioners of the use of HRT in this population.
Screening and providing treatment for negative symptoms and cognitive difficulties
Will examine the prevalence of negative symptoms and cognitive deficits, which are highly prevalent and underpin the poor functional outcomes observed in people affected by psychotic disorders. There is evidence that nutritional supplements can be effective in improving these domains, yet they are rarely prescribed. This work package will develop a screening protocol and evaluate a personalised medicine approach for adjunctive nutritional supplementation.
Discontinuation of anitpsychotic medications
The majority of clinical guidelines recommend that antipsychotic medications are continued for between one to three years after an individual has recovered. However, unfortunately, there are high relapse rates in this population, but not everyone experiences a relapse, and therefore, it is a clinical conundrum as to whether medications should be continued or reduced and discontinued. This work package will develop clinical guidelines on how to reduce or stop antipsychotic medication and will co-develop and evaluate a clinical decision support system to provide individuals with more accurate information on their likely outcome following discontinuation.

